English  |  正體中文  |  简体中文  |  總筆數 :0  
造訪人次 :  52688200    線上人數 :  893
教育部委託研究計畫      計畫執行:國立臺灣大學圖書館
 
臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)
關於TAIR

瀏覽

消息

著作權

相關連結

"_"的相關文件

回到依作者瀏覽
依題名排序 依日期排序

顯示項目 71-120 / 4992 (共100頁)
<< < 1 2 3 4 5 6 7 8 9 10 > >>
每頁顯示[10|25|50]項目

機構 日期 題名 作者
國立成功大學 2024-12-18 Planar XY magnetic glass state in the Gd2ScNbO7 pyrochlore Mauws;C;Beare;J;Rutherford;M, R.;Su;Y;Sharma;S;Nugent;M;Lee;M, K.;Chang;L, J.;Dunsiger;S, R.;Gardner;J, S.;Luke;G, M.;Wiebe;C, R.
國立成功大學 2024-12-18 Atomic oxygen ion retrieval from 630.0 nm airglow during geomagnetically quiet periods: a mid-latitude case study near Irkutsk Duann;Y;Chang;L, C.;Chiu;Y, -c.;Salinas;C, C. C. J. H.;Dmitriev;A, V.;Ratovsky;K, G.;Medvedeva;I, V.;Vasilyev;R;Mikhalev;A, V.;Liu;J, Y.;Lin;C, H.;Fang;T, -w.
國立成功大學 2024-12-15 Exploit and elucidate chaperone assisted PET hydrolase for upcycling plastics Ting;Wan-Wen;Yu;Jie-Yao;Hsiang;Chuan-Chieh;Tan;Shih-;I;Chang;Chang-Chun;Huang;Hsiang-Ling;Yu;Chi-Hua;Hu;Ruei-En;Ma;Hsing-Ning;Ng;-Son, I.
國立成功大學 2024-12-15 An ultrafast, stable and highly reversible nickel magnesium vanadate cathode for magnesium ion batteries Thirbika;S;Kaveevivitchai;W;Prabhu;Ramesh, M.
國立成功大學 2024-12-15 An ultrafast, stable and highly reversible nickel magnesium vanadate cathode for magnesium ion batteries Thirbika;S;Kaveevivitchai;W;Prabhu;Ramesh, M.
國立成功大學 2024-12-1 Tislelizumab (TIS) plus chemotherapy (CT) vs placebo (PBO) plus CT as fi rst-line (1L) treatment for recurrent or metastatic nasopharyngeal cancer (NPC): 3-year follow-up from the RATIONALE-309 study Fang;W, F.;Pan;J;Wang;H;Qu;S;Chen;N;Chen;X;Sun;Y;He;X;Hu;C;Lin;L;Yen;C, J.;Wu;Y;Yuan;S;Chen;C;Yang;Y;Lean;S;Zhang;L
國立成功大學 2024-12-1 Tislelizumab (TIS) plus chemotherapy (CT) vs placebo (PBO) plus CT as fi rst-line (1L) treatment for recurrent or metastatic nasopharyngeal cancer (NPC): 3-year follow-up from the RATIONALE-309 study Fang;W, F.;Pan;J;Wang;H;Qu;S;Chen;N;Chen;X;Sun;Y;He;X;Hu;C;Lin;L;Yen;C, J.;Wu;Y;Yuan;S;Chen;C;Yang;Y;Lean;S;Zhang;L
國立成功大學 2024-12-1 Tislelizumab (TIS) plus chemotherapy (CT) vs placebo (PBO) plus CT as fi rst-line (1L) treatment for recurrent or metastatic nasopharyngeal cancer (NPC): 3-year follow-up from the RATIONALE-309 study Fang;W, F.;Pan;J;Wang;H;Qu;S;Chen;N;Chen;X;Sun;Y;He;X;Hu;C;Lin;L;Yen;C, J.;Wu;Y;Yuan;S;Chen;C;Yang;Y;Lean;S;Zhang;L
國立成功大學 2024-12-1 Tislelizumab (TIS) plus chemotherapy (CT) vs placebo (PBO) plus CT as fi rst-line (1L) treatment for recurrent or metastatic nasopharyngeal cancer (NPC): 3-year follow-up from the RATIONALE-309 study Fang;W, F.;Pan;J;Wang;H;Qu;S;Chen;N;Chen;X;Sun;Y;He;X;Hu;C;Lin;L;Yen;C, J.;Wu;Y;Yuan;S;Chen;C;Yang;Y;Lean;S;Zhang;L
國立成功大學 2024-12-1 Tislelizumab (TIS) plus chemotherapy (CT) vs placebo (PBO) plus CT as fi rst-line (1L) treatment for recurrent or metastatic nasopharyngeal cancer (NPC): 3-year follow-up from the RATIONALE-309 study Fang;W, F.;Pan;J;Wang;H;Qu;S;Chen;N;Chen;X;Sun;Y;He;X;Hu;C;Lin;L;Yen;C, J.;Wu;Y;Yuan;S;Chen;C;Yang;Y;Lean;S;Zhang;L
國立成功大學 2024-12-1 Tislelizumab (TIS) plus chemotherapy (CT) vs placebo (PBO) plus CT as fi rst-line (1L) treatment for recurrent or metastatic nasopharyngeal cancer (NPC): 3-year follow-up from the RATIONALE-309 study Fang;W, F.;Pan;J;Wang;H;Qu;S;Chen;N;Chen;X;Sun;Y;He;X;Hu;C;Lin;L;Yen;C, J.;Wu;Y;Yuan;S;Chen;C;Yang;Y;Lean;S;Zhang;L
國立成功大學 2024-12-1 Tislelizumab (TIS) plus chemotherapy (CT) vs placebo (PBO) plus CT as fi rst-line (1L) treatment for recurrent or metastatic nasopharyngeal cancer (NPC): 3-year follow-up from the RATIONALE-309 study Fang;W, F.;Pan;J;Wang;H;Qu;S;Chen;N;Chen;X;Sun;Y;He;X;Hu;C;Lin;L;Yen;C, J.;Wu;Y;Yuan;S;Chen;C;Yang;Y;Lean;S;Zhang;L
國立成功大學 2024-12-1 Tislelizumab (TIS) plus chemotherapy (CT) vs placebo (PBO) plus CT as fi rst-line (1L) treatment for recurrent or metastatic nasopharyngeal cancer (NPC): 3-year follow-up from the RATIONALE-309 study Fang;W, F.;Pan;J;Wang;H;Qu;S;Chen;N;Chen;X;Sun;Y;He;X;Hu;C;Lin;L;Yen;C, J.;Wu;Y;Yuan;S;Chen;C;Yang;Y;Lean;S;Zhang;L
國立成功大學 2024-12 DERMATOLOGISTS' PERSPECTIVES AND REAL-WORLD ASSESSMENT OF ALOPECIA AREATA SEVERITY AMONG ADULTS IN TAIWAN Chen;Cc;Yang;Cc;Lin;S;Austin;J;Kurosky;S;Hanson;Ka;Yen;M;Anderson;P;Encinas;Ga;Marwaha;S;Chen;A;Chung;Wh
國立成功大學 2024-12 A pooled analysis of trastuzumab deruxtecan in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer with brain metastases Andre;F;Cortes;J;Curigliano;G;Modi;S;Li;W;Park;Y, H.;Chung;W, -p.;Kim;S, -b.;Yamashita;T;Pedrini;J, L.;Im;S, -a.;Tseng;L, -m.;Harbeck;N;Krop;I;Nakatani;S;Tecson;K;Ashfaque;S;Egorov;A;Hurvitz;S, A.
國立成功大學 2024-12 Enfortumab vedotin plus pembrolizumab (EV plus P) vs chemotherapy (Chemo) in previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC): Pan-Asian subgroup analysis from EV-302/KEYNOTE-A39 Kikuchi;E;Heijden, van der;M, S.;Valderrama, Perez;B;Gupta;S;Bedke;J;Shin;S, J.;Li;J-R;Guo;J;Danchaivijitr;P;Kanesvaran;R;Park;S, H.;Su;W-P;Kandori;S;Bae;W, K.;Wong;A, S.;Lu;J;Yu;X;Shetty;A;Bavle;A, A. A.;Powles;T, B.
國立成功大學 2024-12 Enfortumab vedotin plus pembrolizumab (EV plus P) vs chemotherapy (Chemo) in previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC): Pan-Asian subgroup analysis from EV-302/KEYNOTE-A39 Kikuchi;E;Heijden, van der;M, S.;Valderrama, Perez;B;Gupta;S;Bedke;J;Shin;S, J.;Li;J-R;Guo;J;Danchaivijitr;P;Kanesvaran;R;Park;S, H.;Su;W-P;Kandori;S;Bae;W, K.;Wong;A, S.;Lu;J;Yu;X;Shetty;A;Bavle;A, A. A.;Powles;T, B.
國立成功大學 2024-12 Collisional-Radiative modeling of unresolved transition array spectra near 200AA from W17+-W25+ emissions for diagnostics of ITER edge plasma Nishimura;R;Oishi;T;Murakami;I;Kato;D;Sakaue;H, A.;Gupta;S;Ohashi;H;Goto;M;Kawamoto;Y;Kawate;T;Takahashi;H;Tobita;K
國立成功大學 2024-12 ARE DIFFERENT GENERATIONS OF CERAMIC-ON- CERAMIC IMPLANTS MORE COST-EFFECTIVE THAN METAL-ON-POLYETHYLENE IMPLANTS IN PRIMARY TOTAL HIP ARTHROPLASTY? Ku;L, J.;Huang;Y;Tai;T, W.;Hsu;S, H.;Ling;D;Wang;J, D.
國立成功大學 2024-12 Enfortumab vedotin plus pembrolizumab (EV plus P) vs chemotherapy (Chemo) in previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC): Pan-Asian subgroup analysis from EV-302/KEYNOTE-A39 Kikuchi;E;Heijden, van der;M, S.;Valderrama, Perez;B;Gupta;S;Bedke;J;Shin;S, J.;Li;J-R;Guo;J;Danchaivijitr;P;Kanesvaran;R;Park;S, H.;Su;W-P;Kandori;S;Bae;W, K.;Wong;A, S.;Lu;J;Yu;X;Shetty;A;Bavle;A, A. A.;Powles;T, B.
國立成功大學 2024-12 A pooled analysis of trastuzumab deruxtecan in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer with brain metastases Andre;F;Cortes;J;Curigliano;G;Modi;S;Li;W;Park;Y, H.;Chung;W, -p.;Kim;S, -b.;Yamashita;T;Pedrini;J, L.;Im;S, -a.;Tseng;L, -m.;Harbeck;N;Krop;I;Nakatani;S;Tecson;K;Ashfaque;S;Egorov;A;Hurvitz;S, A.
國立成功大學 2024-12 A pooled analysis of trastuzumab deruxtecan in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer with brain metastases Andre;F;Cortes;J;Curigliano;G;Modi;S;Li;W;Park;Y, H.;Chung;W, -p.;Kim;S, -b.;Yamashita;T;Pedrini;J, L.;Im;S, -a.;Tseng;L, -m.;Harbeck;N;Krop;I;Nakatani;S;Tecson;K;Ashfaque;S;Egorov;A;Hurvitz;S, A.
國立成功大學 2024-12 Collisional-Radiative modeling of unresolved transition array spectra near 200AA from W17+-W25+ emissions for diagnostics of ITER edge plasma Nishimura;R;Oishi;T;Murakami;I;Kato;D;Sakaue;H, A.;Gupta;S;Ohashi;H;Goto;M;Kawamoto;Y;Kawate;T;Takahashi;H;Tobita;K
國立成功大學 2024-12 Influence of endovascular surgery on abdominal aortic aneurysm management strategies from a national health insurance database survey Chen;Wei-Ling;Kan;Chung-Dann;Huang;Yi-Ting;Shih;Hsin-;I
國立成功大學 2024-12 Surveillance of pathogenic yeasts in hospital environments in Taiwan in 2020 Tsai;De-Jiun;Hsieh;Li-Yun;Chung;Pei-Jung;Chen;Yin-Zhi;Jhou;Yi-Jyun;Tseng;Kuo-Yun;Yang;Chia-Jui;Yeh;Yen-Cheng;Lin;Seng-Yi;Lee;Susan, Shin-Jung;Wu;Ting-;I;Chiang;Tsung-Ta;Chou;Chien-Hsuan;Miu;Wei-Chieh;Liu;Po-Yu;Lu;Chin-Te;Lee;Yuan-Ti;Syu;Yu-Ling;Hsu;Gwo-Jong;Chen;Yee-Chun;Lee;Nan-Yao;Chen;Chang-Hua;Yang;Ching-Cheng;Wang;Lih-Shinn;Liu;Jien-Wei;Kao;Chin-Chuan;Chang;Ya-Ting;Liu;Keh-Sen;Hu;Bor-Shen;Hsu;Che-Han;Huang;Yi-Ching;Lo;Hsiu-Jung
國立成功大學 2024-12 Collisional-Radiative modeling of unresolved transition array spectra near 200AA from W17+-W25+ emissions for diagnostics of ITER edge plasma Nishimura;R;Oishi;T;Murakami;I;Kato;D;Sakaue;H, A.;Gupta;S;Ohashi;H;Goto;M;Kawamoto;Y;Kawate;T;Takahashi;H;Tobita;K
國立成功大學 2024-12 A pooled analysis of trastuzumab deruxtecan in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer with brain metastases Andre;F;Cortes;J;Curigliano;G;Modi;S;Li;W;Park;Y, H.;Chung;W, -p.;Kim;S, -b.;Yamashita;T;Pedrini;J, L.;Im;S, -a.;Tseng;L, -m.;Harbeck;N;Krop;I;Nakatani;S;Tecson;K;Ashfaque;S;Egorov;A;Hurvitz;S, A.
國立成功大學 2024-12 Control of Corner Separation in Compressor Cascade Using Biomimetic Fish Scales Structure Shen;Jin-Long;Yeh;Szu-;I
國立成功大學 2024-12 DERMATOLOGISTS' PERSPECTIVES AND REAL-WORLD ASSESSMENT OF ALOPECIA AREATA SEVERITY AMONG ADULTS IN TAIWAN Chen;Cc;Yang;Cc;Lin;S;Austin;J;Kurosky;S;Hanson;Ka;Yen;M;Anderson;P;Encinas;Ga;Marwaha;S;Chen;A;Chung;Wh
國立成功大學 2024-12 A pooled analysis of trastuzumab deruxtecan in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer with brain metastases Andre;F;Cortes;J;Curigliano;G;Modi;S;Li;W;Park;Y, H.;Chung;W, -p.;Kim;S, -b.;Yamashita;T;Pedrini;J, L.;Im;S, -a.;Tseng;L, -m.;Harbeck;N;Krop;I;Nakatani;S;Tecson;K;Ashfaque;S;Egorov;A;Hurvitz;S, A.
國立成功大學 2024-12 Enfortumab vedotin plus pembrolizumab (EV plus P) vs chemotherapy (Chemo) in previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC): Pan-Asian subgroup analysis from EV-302/KEYNOTE-A39 Kikuchi;E;Heijden, van der;M, S.;Valderrama, Perez;B;Gupta;S;Bedke;J;Shin;S, J.;Li;J-R;Guo;J;Danchaivijitr;P;Kanesvaran;R;Park;S, H.;Su;W-P;Kandori;S;Bae;W, K.;Wong;A, S.;Lu;J;Yu;X;Shetty;A;Bavle;A, A. A.;Powles;T, B.
國立成功大學 2024-12 Collisional-Radiative modeling of unresolved transition array spectra near 200AA from W17+-W25+ emissions for diagnostics of ITER edge plasma Nishimura;R;Oishi;T;Murakami;I;Kato;D;Sakaue;H, A.;Gupta;S;Ohashi;H;Goto;M;Kawamoto;Y;Kawate;T;Takahashi;H;Tobita;K
國立成功大學 2024-12 A pooled analysis of trastuzumab deruxtecan in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer with brain metastases Andre;F;Cortes;J;Curigliano;G;Modi;S;Li;W;Park;Y, H.;Chung;W, -p.;Kim;S, -b.;Yamashita;T;Pedrini;J, L.;Im;S, -a.;Tseng;L, -m.;Harbeck;N;Krop;I;Nakatani;S;Tecson;K;Ashfaque;S;Egorov;A;Hurvitz;S, A.
國立成功大學 2024-12 DERMATOLOGISTS' PERSPECTIVES AND REAL-WORLD ASSESSMENT OF ALOPECIA AREATA SEVERITY AMONG ADULTS IN TAIWAN Chen;Cc;Yang;Cc;Lin;S;Austin;J;Kurosky;S;Hanson;Ka;Yen;M;Anderson;P;Encinas;Ga;Marwaha;S;Chen;A;Chung;Wh
國立成功大學 2024-12 Collisional-Radiative modeling of unresolved transition array spectra near 200AA from W17+-W25+ emissions for diagnostics of ITER edge plasma Nishimura;R;Oishi;T;Murakami;I;Kato;D;Sakaue;H, A.;Gupta;S;Ohashi;H;Goto;M;Kawamoto;Y;Kawate;T;Takahashi;H;Tobita;K
國立成功大學 2024-12 A pooled analysis of trastuzumab deruxtecan in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer with brain metastases Andre;F;Cortes;J;Curigliano;G;Modi;S;Li;W;Park;Y, H.;Chung;W, -p.;Kim;S, -b.;Yamashita;T;Pedrini;J, L.;Im;S, -a.;Tseng;L, -m.;Harbeck;N;Krop;I;Nakatani;S;Tecson;K;Ashfaque;S;Egorov;A;Hurvitz;S, A.
國立成功大學 2024-12 DERMATOLOGISTS' PERSPECTIVES AND REAL-WORLD ASSESSMENT OF ALOPECIA AREATA SEVERITY AMONG ADULTS IN TAIWAN Chen;Cc;Yang;Cc;Lin;S;Austin;J;Kurosky;S;Hanson;Ka;Yen;M;Anderson;P;Encinas;Ga;Marwaha;S;Chen;A;Chung;Wh
國立成功大學 2024-12 Enfortumab vedotin plus pembrolizumab (EV plus P) vs chemotherapy (Chemo) in previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC): Pan-Asian subgroup analysis from EV-302/KEYNOTE-A39 Kikuchi;E;Heijden, van der;M, S.;Valderrama, Perez;B;Gupta;S;Bedke;J;Shin;S, J.;Li;J-R;Guo;J;Danchaivijitr;P;Kanesvaran;R;Park;S, H.;Su;W-P;Kandori;S;Bae;W, K.;Wong;A, S.;Lu;J;Yu;X;Shetty;A;Bavle;A, A. A.;Powles;T, B.
國立成功大學 2024-12 The efficacy, safety and cell-free DNA of perioperative leucovorin, oxaliplatin, docetaxel and S-1 (LOTS) for locally advanced gastric or gastroesophageal junction adenocarcinoma: A prospective phase II trial Yen;C, C. C.;Chen;I, S.;Chao;Y, J.;Bai;L-Y;Tsai;C, Y.;Jui;P;Hsu;C, Y.;Liao;T, K.;Huang;C-J;Liu;I, T.;Shan;Y-S;Yen;C, J.
國立成功大學 2024-12 Collisional-Radiative modeling of unresolved transition array spectra near 200AA from W17+-W25+ emissions for diagnostics of ITER edge plasma Nishimura;R;Oishi;T;Murakami;I;Kato;D;Sakaue;H, A.;Gupta;S;Ohashi;H;Goto;M;Kawamoto;Y;Kawate;T;Takahashi;H;Tobita;K
國立成功大學 2024-12 Enfortumab vedotin plus pembrolizumab (EV plus P) vs chemotherapy (Chemo) in previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC): Pan-Asian subgroup analysis from EV-302/KEYNOTE-A39 Kikuchi;E;Heijden, van der;M, S.;Valderrama, Perez;B;Gupta;S;Bedke;J;Shin;S, J.;Li;J-R;Guo;J;Danchaivijitr;P;Kanesvaran;R;Park;S, H.;Su;W-P;Kandori;S;Bae;W, K.;Wong;A, S.;Lu;J;Yu;X;Shetty;A;Bavle;A, A. A.;Powles;T, B.
國立成功大學 2024-12 DERMATOLOGISTS' PERSPECTIVES AND REAL-WORLD ASSESSMENT OF ALOPECIA AREATA SEVERITY AMONG ADULTS IN TAIWAN Chen;Cc;Yang;Cc;Lin;S;Austin;J;Kurosky;S;Hanson;Ka;Yen;M;Anderson;P;Encinas;Ga;Marwaha;S;Chen;A;Chung;Wh
國立成功大學 2024-12 Collisional-Radiative modeling of unresolved transition array spectra near 200AA from W17+-W25+ emissions for diagnostics of ITER edge plasma Nishimura;R;Oishi;T;Murakami;I;Kato;D;Sakaue;H, A.;Gupta;S;Ohashi;H;Goto;M;Kawamoto;Y;Kawate;T;Takahashi;H;Tobita;K
國立成功大學 2024-12 A pooled analysis of trastuzumab deruxtecan in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer with brain metastases Andre;F;Cortes;J;Curigliano;G;Modi;S;Li;W;Park;Y, H.;Chung;W, -p.;Kim;S, -b.;Yamashita;T;Pedrini;J, L.;Im;S, -a.;Tseng;L, -m.;Harbeck;N;Krop;I;Nakatani;S;Tecson;K;Ashfaque;S;Egorov;A;Hurvitz;S, A.
國立成功大學 2024-12 Enfortumab vedotin plus pembrolizumab (EV plus P) vs chemotherapy (Chemo) in previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC): Pan-Asian subgroup analysis from EV-302/KEYNOTE-A39 Kikuchi;E;Heijden, van der;M, S.;Valderrama, Perez;B;Gupta;S;Bedke;J;Shin;S, J.;Li;J-R;Guo;J;Danchaivijitr;P;Kanesvaran;R;Park;S, H.;Su;W-P;Kandori;S;Bae;W, K.;Wong;A, S.;Lu;J;Yu;X;Shetty;A;Bavle;A, A. A.;Powles;T, B.
國立成功大學 2024-12 Collisional-Radiative modeling of unresolved transition array spectra near 200AA from W17+-W25+ emissions for diagnostics of ITER edge plasma Nishimura;R;Oishi;T;Murakami;I;Kato;D;Sakaue;H, A.;Gupta;S;Ohashi;H;Goto;M;Kawamoto;Y;Kawate;T;Takahashi;H;Tobita;K
國立成功大學 2024-12 A pooled analysis of trastuzumab deruxtecan in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer with brain metastases Andre;F;Cortes;J;Curigliano;G;Modi;S;Li;W;Park;Y, H.;Chung;W, -p.;Kim;S, -b.;Yamashita;T;Pedrini;J, L.;Im;S, -a.;Tseng;L, -m.;Harbeck;N;Krop;I;Nakatani;S;Tecson;K;Ashfaque;S;Egorov;A;Hurvitz;S, A.
國立成功大學 2024-12 A pooled analysis of trastuzumab deruxtecan in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer with brain metastases Andre;F;Cortes;J;Curigliano;G;Modi;S;Li;W;Park;Y, H.;Chung;W, -p.;Kim;S, -b.;Yamashita;T;Pedrini;J, L.;Im;S, -a.;Tseng;L, -m.;Harbeck;N;Krop;I;Nakatani;S;Tecson;K;Ashfaque;S;Egorov;A;Hurvitz;S, A.
國立成功大學 2024-12 Enfortumab vedotin plus pembrolizumab (EV plus P) vs chemotherapy (Chemo) in previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC): Pan-Asian subgroup analysis from EV-302/KEYNOTE-A39 Kikuchi;E;Heijden, van der;M, S.;Valderrama, Perez;B;Gupta;S;Bedke;J;Shin;S, J.;Li;J-R;Guo;J;Danchaivijitr;P;Kanesvaran;R;Park;S, H.;Su;W-P;Kandori;S;Bae;W, K.;Wong;A, S.;Lu;J;Yu;X;Shetty;A;Bavle;A, A. A.;Powles;T, B.
國立成功大學 2024-12 Collisional-Radiative modeling of unresolved transition array spectra near 200AA from W17+-W25+ emissions for diagnostics of ITER edge plasma Nishimura;R;Oishi;T;Murakami;I;Kato;D;Sakaue;H, A.;Gupta;S;Ohashi;H;Goto;M;Kawamoto;Y;Kawate;T;Takahashi;H;Tobita;K

顯示項目 71-120 / 4992 (共100頁)
<< < 1 2 3 4 5 6 7 8 9 10 > >>
每頁顯示[10|25|50]項目